EC Number   |
Protein Variants |
Reference |
|---|
    2.5.1.15 | A383G |
dominant drug resistance mutation. Mutation subtly alters the intricate enzyme-4-amino benzoic acid-sulfadoxine interactions such that DHPS affinity for 4-amino benzoic acid is diminished only moderately, but its affinity for sulfadoxine is changed substantially |
-, 759490 |
| 2.5.1.15 | A383G |
drug resistance mutation. Resistance mutations subtly alters the intricate enzyme/4-aminobenzoate/sulfadoxine interactions such that DHPS affinity for 4-aminobenzoate is diminished only moderately, but its affinity for sulfadoxine is changed substantially |
-, 759490 |
| 2.5.1.15 | A383G |
high prevalence amino acid mutation observed in Hormozgan Province, southern Iran. The high prevalence of point mutation of Pvdhps genotype necessitates change in programmes and guidelines to eliminate Plasmodium vivax in future |
759689 |
| 2.5.1.15 | A383G |
mutation does not much influence the enzyme catalytic activity. Mutant becomes 13fold more resistant to sulfadoxine than the wild type |
758651 |
| 2.5.1.15 | A383G |
the mutation confers resistance to sulfadoxine |
759490 |
| 2.5.1.15 | A383G/A553G |
mutation does not much influence the enzyme catalytic activity. Mutant becomes 13fold more resistant to sulfadoxine than the wild type |
758651 |
| 2.5.1.15 | A437G |
little association with between mutantion and sulfa drug resistance in patients |
671349 |
| 2.5.1.15 | A437G |
mutant enzyme is resistant against inhibition by sulfadoxine and sulfpyridine (inhibitors of wild-type enzyme) |
661908 |
| 2.5.1.15 | A437G |
mutant enzyme shows increased affinity for 4-aminobenzoate along with reduced binding and efficacy of sulfa drugs. (kcat/Km) for 4-aminobenzoate is increased by 6fold. Mutation enhances the dynamic flexibility of loop D2 |
759184 |
| 2.5.1.15 | A437G/A581G |
mutant enzyme is resistant against inhibition by sulfadoxine, sulfpyridine, sulfadimethoxine, sulfamethoxazole, sulfaquinoxaline and sulfisoxazole (inhibitors of wild-type enzyme) |
661908 |
